EYPT Q3 2018 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$486,000+26.2% YoY

Gross Profit

-$6M-1182.5% margin

Operating Income

-$14M-2788.9% margin

Net Income

-$33M-6816.0% margin

EPS (Diluted)

$-4.41

QoQ Revenue Growth

-32.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$89M

Total Liabilities

$41M

Stockholders' Equity

$48M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$486,000	$385,000	+26.2%
Gross Profit	-$6M	$385,000	-1592.7%
Operating Income	-$14M	-$6M	-125.7%
Net Income	-$33M	-$6M	-453.7%

Revenue Segments

Royalty

$430,00088%

Collaborative Research and Development

$56,00012%